Biotech Stocks Could Use A Win — Will The First Quarter Offer That?Investors Business Daily • 04/08/21
Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid ArthritisBenzinga • 04/08/21
Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid ArthritisGlobeNewsWire • 04/08/21
The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple SclerosisGlobeNewsWire • 04/07/21
Biogen Inc. (BIIB) Down 1.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 03/05/21
Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North CarolinaGlobeNewsWire • 03/04/21
Biogen Inc. (BIIB) CEO Michel Vounatsos Presents at Cowen 41st Annual Health Care Conference (Transcript)Seeking Alpha • 03/02/21
Life Science Cares and Biogen Foundation Help Launch Food For Free's Just Eats ProgramGlobeNewsWire • 02/24/21